GSS Annual Poster Session - Travel Award Winners Announced
Thursday, June 7, 2018
Congratulations to our most recent GSS poster session Travel Award Winners!
Lara Terry, 3rd year student in David Yule Lab: 2nd place – Title: Effects of Missense Mutations on Inositol 1,4,5-trisphosphate Receptor Mediated Calcium Release.
Si Chen, 4th year student in Chen Yan lab: 3rd place – Title: PDE10A Inhibition and Deficiency Attenuate Pathological Cardiac Remodeling
Pharmacology Alumni Named Associate Dean
Friday, May 11, 2018
Jennifer Mathews, PhD has been named the Associate Dean for the Albany College of Pharmacy and Health Sciences - Vermont Campus.
Dr. Mathews earned her doctorate in Pharmacology from the University of Rochester in 2007, her field(s) of interest as a student were Neuropharmacology, Opioid receptors, Pain, Tolerance, Antinociception
Her responsibilities will include execution of the pharmacy program; supervision of faculty; campus operations; and coordination of the development, implementation, and assessment of initiatives that support the programs on the Vermont Campus, which also include a Master’s program in Pharmaceutical Sciences.
Congratulations to Dr. Mathews!Read More: Pharmacology Alumni Named Associate Dean
Brandon Berry Recipient of a two-year American Heart Association Predoctoral Fellowship & Professional Member of the AHA July 1, 2018 – June 30, 2020
Monday, April 23, 2018
Brandon Berry, graduate student in the laboratory of Dr. Andrew P. Wojtovich was awarded a two-year American Heart Association Predoctoral Fellowship entitled, “Optogenetic Control of Mitochondrial Function to Protect Against Ischemia Reperfusion Injury”.
Mitochondria are central mediators of cell death following the pathologic stress of ischemia reperfusion (IR) injury during heart attack or stroke. However, mitochondria can be targeted with specific interventions that inhibit cell death following IR. The mitochondrial protonmotive force (PMF) is coupled to ATP synthesis, and controls ion gradients and oxidative stress. Dissipation of the PMF in IR injury results in cellular damage and death. Interestingly, mild uncoupling of the PMF from ATP synthesis using low-dose protonophores protects against IR injury. It is unclear whether uncoupling triggers protective signaling, or if uncoupling itself is the effector of protection. Further, pharmacologic tools lack temporal and spatial control, obscuring when and where uncoupling is sufficient to protect against IR injury. Uncoupling mitochondria using optogenetics addresses the spatiotemporal challenge of using protonophores. Spatiotemporal control can determine if the mechanism of uncoupling confers protection before ischemia (preconditioning), during ischemia, during reperfusion, or after reperfusion (postconditioning). Overall, using our novel optogenetic tools, this project aims to test how precise, selective, reversible uncoupling is sufficient to elicit cellular responses that protect against IR injury.
Cindy Wang Wins America’s Got Regulatory Science Talent Competition
Monday, March 5, 2018
Xiaowen (Cindy) Wang, M.S., a graduate student in the Cellular and Molecular Pharmacology and Physiology PhD Program placed first in the 5th annual "America’s Got Regulatory Science Talent" competition for her proposal “Dr. Data: An Integrated Drug Repurposing Database for Identifying New Indications of FDA Approved Drugs”
To read more about Cindy’s proposal and the competition, please visit the CTSI Stories website.
This is how a brain gets hooked on opioids like it craves a candy bar
Friday, February 23, 2018
Eating a candy bar and injecting heroin each trigger a part of the brain that reinforces feeling good.
“Pleasure is pleasure,” said Jean Bidlack, a researcher at the University of Rochester Medical Center who is looking at a different way to treat opioid addiction.
While much of current thinking is focused on opioid receptors, Bidlack is going to look at how the neurotransmitter dopamine affects the desire for drugs.
“A candy bar will give you a little bit of dopamine release and give you pleasure,” said Bidlack, a professor of pharmacology and physiology. Regular ingestion can turn into a habit, but stopping isn’t likely to fundamentally change your life.
“Drugs of abuse like opioids will give you a very high dopamine level,” Bidlack said. “The brain adapts and says, ‘I want that high dopamine level all the time.’ And then when you don’t have it, that’s when the craving is very, very strong.”Read More: This is how a brain gets hooked on opioids like it craves a candy bar
Bidlack Receives NIH Grant For Opioid Addiction Research
Tuesday, February 13, 2018
From left: Dr. Janice Harbin, CEO at Anthony L. Jordan Health Center, Dr. Jean Bidlack, Mr. Michael Leary, CEO at Regional Primary Care Network, and Louise Slaughter.
A groundbreaking treatment for opioid addiction could come from local research. Monday, Congresswoman Louise Slaughter announced a $200,000 award from the NIH to a University of Rochester lab that is studying a possible new treatment for addiction.
Dr. Jean Bidlack of the University of Rochester Medical Center is involved in the research. “What I’m looking at is a hormone that has been shown in animals to reduce both the preference for sweets and alcohol by decreasing dopamine levels,” Dr. Bidlack explained. The money for the research of part of the federal budget approved last week.
The actual award is for 2 years, totaling of $385,000.
Congratulations Dr. Bidlack!